S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer

被引:168
|
作者
Diederichs, S
Bulk, E
Steffen, B
Ji, P
Tickenbrock, L
Lang, K
Zänker, KS
Metzger, R
Schneider, PM
Gerke, V
Thomas, M
Berdel, WE
Serve, H
Müller-Tidow, C
机构
[1] Univ Munster, Dept Med Hematol Oncol, D-48129 Munster, Germany
[2] Univ Witten Herdecke, Dept Immunol, D-5810 Witten, Germany
[3] Univ Cologne, Dept Visceral & Vasc Surg, Cologne, Germany
[4] Univ Munster, Inst Med Biochem, Ctr Mol Biol & Inflammat, D-48129 Munster, Germany
关键词
D O I
10.1158/0008-5472.CAN-04-2004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Distant metastasis is the predominant cause of death in early-stage non-small cell lung cancer (NSCLC). Currently, it is impossible to predict the occurrence of metastasis at early stages and thereby separate patients who could be cured by surgical resection alone from patients who would benefit from additional chemotherapy. In this study, we applied a comparative microarray approach to identify gene expression differences between early-stage NSCLC patients whose cancer ultimately did or did not metastasize during the course of their disease. Transcriptional profiling of 82 microarrays from two patient groups revealed differential expression of several gene families including known predictors of metastasis (e.g., matrix metalloproteinases). In addition, we found S100P, S100A2, trypsinogen C (TRY6), and trypsinogen IVb (PRSS3) to be overexpressed in tumors that metastasized during the course of the disease. In a third group of 42 patients, we confirmed the induction of S100 proteins and trypsinogens in metastasizing tumors and its significant correlation with survival by real-time quantitative reverse transcription-PCR. Overexpression of S100A2, S100P, or PRSS3 in NSCLC cell cultures led to increased transendothelial migration, corroborating the role of S100A2, S100P, and PRSS3 in the metastatic process. Taken together, we provide evidence that expression of S100 proteins and trypsinogens is associated with metastasis and predicts survival in early stages of NSCLC. For the first time, this implicates a role of S100 proteins and trypsinogens in the metastatic process of early-stage NSCLC.
引用
收藏
页码:5564 / 5569
页数:6
相关论文
共 50 条
  • [41] Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
    Shukla, Nikhil
    Hanna, Nasser
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 51 - 60
  • [42] Is Brain MRI Unnecessary for Early-Stage Non-Small Cell Lung Cancer?
    Bizzi, Alberto
    Pascuzzo, Riccardo
    RADIOLOGY, 2022, 303 (03) : 644 - 645
  • [43] Disparities in surgical resection of early-stage non-small cell lung cancer
    Jazieh, AR
    Kyasa, MJ
    Sethuraman, G
    Howington, J
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 123 (06): : 1173 - 1176
  • [44] Waiting times in early-stage non-small cell lung cancer (NSCLC)
    Saint-Jacques, Nathalie
    Rayson, Daniel
    Al-Fayea, Turki
    Virik, Kiran
    Morzycki, Wojciech
    Younis, Tallal
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (08) : 865 - 870
  • [45] EARLY-STAGE NON-SMALL CELL LUNG CANCER STRATIFYING RECURRENCE RISK
    Saito, T.
    Kono, Y.
    Ueno, Y.
    Maru, N.
    Utsumi, T.
    Matsui, H.
    Taniguchi, Y.
    Hino, H.
    Tsuta, K.
    Honda, O.
    Murakawa, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S559 - S560
  • [46] Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer
    Inamura, Kentaro
    JAMA ONCOLOGY, 2021, 7 (04) : 637 - 638
  • [47] Docetaxel in neoadjuvant therapy of early-stage non-small cell lung cancer
    Betticher, DC
    ONKOLOGIE, 2003, 26 : 33 - 36
  • [48] Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017
    Donington, Jessica S.
    Kim, Young Tae
    Tong, Betty
    Moreira, Andre L.
    Bessich, Jamie
    Weiss, Kathleen D.
    Colson, Yolonda L.
    Wigle, Dennis
    Osarogiagbon, Raymond U.
    Zweig, Jeffrey
    Wakelee, Heather
    Blasberg, Justin
    Daly, Megan
    Backhus, Leah
    Van Schil, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (06) : 767 - 778
  • [49] Role of Segmentectomy in Treatment of Early-Stage Non-Small Cell Lung Cancer
    Hennon, Mark
    Landreneau, Rodney J.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (01) : 59 - 63
  • [50] Resectability versus Operability in Early-Stage Non-Small Cell Lung Cancer
    Streit, Arthur
    Lampridis, Savvas
    Seitlinger, Joseph
    Renaud, Stephane
    Routledge, Tom
    Bille, Andrea
    CURRENT ONCOLOGY REPORTS, 2024, 26 (01) : 55 - 64